How can malignant hyperthermia be distinguished from serotonin syndrome?

Differentiating Malignant Hyperthermia from Serotonin Syndrome

The critical distinguishing features are: malignant hyperthermia occurs exclusively with exposure to volatile anesthetics or succinylcholine during anesthesia, while serotonin syndrome develops from serotonergic medications and presents with hyperreflexia and clonus rather than the uniform rigidity of MH.

Context and Timing

Malignant hyperthermia occurs only in the perioperative setting after exposure to triggering anesthetic agents (volatile anesthetics like sevoflurane, desflurane, isoflurane, or succinylcholine). The onset is typically within 10 minutes to several hours of exposure, though delays up to 40 minutes after discontinuing the triggering agent have been documented 1.

Serotonin syndrome develops within hours of initiating or increasing serotonergic agents (SSRIs, SNRIs, MAOIs, tramadol, MDMA, methamphetamine) or combining multiple serotonergic drugs 2, 3.

Cardinal Clinical Features

Malignant Hyperthermia 1:

• Primary finding: Unexplained, progressive increase in ETCO₂ despite increased minute ventilation (the most consistent early sign)
• Muscle findings: Jaw rigidity (especially with succinylcholine), generalized muscle rigidity with "lead-pipe" quality
• Cardiovascular: Tachycardia (most consistent), variable blood pressure, arrhythmias
• Temperature: Rising core temperature (but may be a late finding)
• Laboratory: Hyperkalemia, respiratory then mixed acidosis, elevated CK, myoglobinuria
• Skin: Hot, flushed, sweaty; mottling in children

Serotonin Syndrome 2, 3, 4:

• Neuromuscular: Clonus (spontaneous, inducible, or ocular) and hyperreflexia - these are the key differentiating features
• Autonomic: Hyperthermia, diaphoresis, tachycardia, mydriasis
• Mental status: Agitation, confusion (not the stupor/rigidity of MH)
• Muscle tone: Increased but with preserved reflexes and clonus, NOT the uniform lead-pipe rigidity of MH

Key Physical Examination Differences

The physical examination is your most powerful tool 2:

• Clonus and hyperreflexia → Serotonin syndrome
• Lead-pipe rigidity without hyperreflexia → Malignant hyperthermia (or neuroleptic malignant syndrome)
• Jaw rigidity immediately after succinylcholine → Malignant hyperthermia

Diagnostic Algorithm

1. Is the patient under anesthesia or recently exposed to volatile anesthetics/succinylcholine?

   • YES → Consider MH first; look for rising ETCO₂ and jaw/generalized rigidity
   • NO → MH is essentially excluded

2. Is there recent serotonergic medication use or drug interaction?

   • YES → Consider serotonin syndrome; check for clonus and hyperreflexia
   • NO → Look for other causes

3. Check reflexes and muscle tone:

   • Hyperreflexia + clonus + preserved mental agitation → Serotonin syndrome
   • Lead-pipe rigidity + no hyperreflexia + obtunded → MH (or NMS if neuroleptics involved)

4. Monitor ETCO₂ (if intubated):

   • Progressive rise despite increased ventilation → MH
   • Normal or mildly elevated → Serotonin syndrome more likely

Treatment Differences

Malignant Hyperthermia 1:

• Immediately discontinue triggering agents
• Dantrolene 2-3 mg/kg IV, then 1 mg/kg every 5 minutes until ETCO₂ <6 kPa and temperature <38.5°C
• Active cooling
• Hyperventilation to control ETCO₂

Serotonin Syndrome 2, 3, 4:

• Discontinue all serotonergic agents
• Benzodiazepines for agitation and muscle rigidity
• Cyproheptadine (5-HT₂A antagonist) 12 mg initially, then 2 mg every 2 hours (though evidence is limited to case reports)
• Supportive care with cooling for severe hyperthermia
• In severe cases: intubation, paralysis, aggressive cooling

Critical Pitfalls

• Do not wait for hyperthermia to diagnose MH - rising ETCO₂ and tachycardia precede temperature elevation 1
• Do not confuse the hyperreflexia of serotonin syndrome with the rigidity of MH - test for clonus 2
• In cases where differentiation is impossible (rare outside anesthesia), benzodiazepines are the safest initial treatment as they benefit both conditions 2
• Neuroleptic malignant syndrome can mimic both but develops over days with neuroleptic use and presents with lead-pipe rigidity like MH but without anesthetic exposure 2, 5

Genetic Considerations

Despite clinical similarities, there is no genetic association between MH, serotonin syndrome, and neuroleptic malignant syndrome 6. MH results from ryanodine receptor (RYR1) mutations, while serotonin syndrome involves 5-HT₁A and 5-HT₂A receptor overstimulation through different mechanisms 2, 3, 6.